Vilobelimab Safe, Well-tolerated in Phase 2 IXPLORE Study

Vilobelimab Safe, Well-tolerated in Phase 2 IXPLORE Study

294451

Vilobelimab Safe, Well-tolerated in Phase 2 IXPLORE Study

Adding vilobelimab (IFX-1) to standard of care treatment is safe and well-tolerated among patients with ANCA-associated vasculitis (AAV), according to top-line results from the ongoing Phase 2 IXPLORE study. Some participants also showed clinical response and remission, although the study was not designed to assess the statistical significance of such findings. “We are pleased to report that vilobelimab was safe and well tolerated in combination with standard of care for patients with ANCA-associated vasculitis in…

You must be logged in to read/download the full post.